---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-25-000081"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2025-04-04T23:59:59+00:00"
generated_at: "2026-05-23T22:02:14.976429+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Neurocrine appoints Sanjay Keswani as CMO effective June 2; Roberts transitions to advisory role

## Summary
- Sanjay Keswani appointed CMO effective June 2, 2025; Eiry Roberts transitions to strategic advisory role after 7 years as CMO.
- Keswani brings >20 yrs pharma/biotech experience; formerly CEO of ImmunoBrain, SVP at Roche, VP at BMS.
- Roberts led INGREZZA expansion, crinecerfont approval as CRENESSITY, and Phase 2 studies for osavampator and NBI-1117568 now moving to registrational.
- Roberts' retirement was announced in July 2023; she remained until replacement onboarded; orderly succession.

## SEC filing metadata
- accession: 0000914475-25-000081
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2025-04-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447525000081/0000914475-25-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447525000081/nbix-20250402.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-25-000081
- JSON: https://secwatch.observer/filing/0000914475-25-000081.json
- Plain text: https://secwatch.observer/filing/0000914475-25-000081.txt

## Key facts
- Executive change
  Eiry W. Roberts departed as Chief Medical Officer at NEUROCRINE BIOSCIENCES INC.
  - Action: succeeded
  - Role: Chief Medical Officer
  source text: Dr. Keswani will succeed Dr. Roberts, who has served as Chief Medical Officer for the past seven years, and who agreed to remain with the Company in a strategic advisory role following her succession by Dr. Keswani.
  evidence_url: https://www.sec.gov/Archives/edgar/data/914475/000091447525000081/0000914475-25-000081-index.htm
- Executive change
  Sanjay Keswani was appointed as Chief Medical Officer at NEUROCRINE BIOSCIENCES INC.
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On April 2, 2025, Sanjay Keswani, M.D. agreed to succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of Neurocrine Biosciences, Inc. (“Neurocrine Biosciences” or the “Company”), effective June 2, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/914475/000091447525000081/0000914475-25-000081-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.